Maternal HIV: Developmental Neurotoxicity - Administrative Supplement

孕产妇艾滋病毒:发育神经毒性 - 行政补充

基本信息

项目摘要

DESCRIPTION (provided by applicant): Although combination antiretroviral therapy (CART) has been highly successful in reducing mother-to-child- transmission (MTCT) in the U.S., globally, MTCT is presently responsible for >1000 new HIV-1 infections each day or more than one new pediatric infection every two minutes. The dopamine (DA) system is a clinically relevant target as evidenced by recent imaging, neurocognitive, and post-mortem examinations of the HIV-1 infected patients. Using a prospective longitudinal design, in this competing renewal we will explore the hypothesis that the development and progression of neurocognitive dysfunction associated with HIV-1, is consequent of, and attributable to, pathology of the DA system, a system highly sensitive to inflammatory processes. Longitudinal studies, while challenging in non-rodent species, are critical for systematically addressing pediatric HIV-1/AIDS, and are also fundamental to our understanding of chronic HIV-1 associated neurological disorders (HAND). The specific aims are: 1) To determine the development and progression of neurocognitive dysfunction consequent to chronic, low-level inflammation and HIV-1 protein exposure. Developmental milestones and an array of tasks directed at the behaviors expressing the prominent components of neurocognitive dysfunction that have been clinically identified will be assessed during the rodent preweaning period, adolescence, adulthood and middle age. 2) To determine the long-term alterations in the major DA receptor subtypes and DA transporter as a candidate neurochemical mechanism for the neurocognitive dysfunction consequent to chronic, low-level inflammation and HIV- 1 protein exposure. Quantitative autoradiography will be used to assess the expression of DA receptors (D1, D2, and D3) and DA transporters (DAT) in the nigrostriatal and mesocorticolimbic pathways of the DA system during adolescence, adulthood and middle age. 3) To determine the integrity of DAT function in the development and progression of neurocognitive dysfunction consequent to chronic, low-level inflammation and HIV-1 protein exposure. DAT function will be studied in a transgenic rat model of chronic HIV-1 protein exposure using in vivo NNF/microdialysis. 4) To determine whether the neurocognitive dysfunction consequent to chronic, low-level inflammation and HIV-1 protein exposure may be treated with currently used agonists or antagonists, or novel agents, targeted to the identified DA system dysfunction. These experiments will establish the functional role of the neurobiological changes in the DA receptors and DAT as a neurochemical mechanism contributing to, if not mediating, the neurocognitive impairments consequent to chronic expression of the HIV-1 transgene. The program goal is to advance the field with a translational model of the core components of cognition relevant to pediatric HIV-1/AIDS as well as to HAND, and more importantly, to identify (normal rats) and validate (the better characterized HIV-1 transgenic rat) novel neurotherapeutics to "tune" the cognition domains afflicted by HIV-1.
描述(由申请人提供):虽然在美国,联合抗逆转录病毒疗法 (CART) 在减少母婴传播 (MTCT) 方面取得了巨大成功,但在全球范围内,MTCT 目前每天导致超过 1000 例新的 HIV-1 感染,或每两分钟超过 1 例新的儿科感染。最近对 HIV-1 感染患者进行的影像学、神经认知和尸检检查证明,多巴胺 (DA) 系统是一个临床相关靶标。使用前瞻性纵向设计,在这一竞争性更新中,我们将探讨这样一个假设:与 HIV-1 相关的神经认知功能障碍的发生和进展是 DA 系统(一个对炎症过程高度敏感的系统)病理学的结果和归因。纵向研究虽然在非啮齿类动物中具有挑战性,但对于系统地解决儿童 HIV-1/AIDS 问题至关重要,并且对于我们了解慢性 HIV-1 相关神经系统疾病 (HAND) 也至关重要。具体目标是: 1) 确定慢性、低水平炎症和 HIV-1 蛋白暴露导致的神经认知功能障碍的发生和进展。将在啮齿类动物断奶前、青春期、成年期和中年期间评估发育里程碑和一系列针对临床上已确定的表现神经认知功能障碍主要成分的行为的任务。 2) 确定主要 DA 受体亚型和 DA 转运蛋白的长期变化,作为慢性、低水平炎症和 HIV-1 蛋白暴露引起的神经认知功能障碍的候选神经化学机制。定量放射自显影将用于评估青春期、成年和中年期间 DA 系统黑质纹状体和中皮质边缘通路中 DA 受体(D1、D2 和 D3)和 DA 转运蛋白(DAT)的表达。 3) 确定 DAT 功能在慢性、低水平炎症和 HIV-1 蛋白暴露导致的神经认知功能障碍的发生和进展中的完整性。将使用体内 NNF/微透析在慢性 HIV-1 蛋白暴露的转基因大鼠模型中研究 DAT 功能。 4) 确定是否可以用目前使用的激动剂或拮抗剂或针对已确定的 DA 系统功能障碍的新型药物来治疗慢性、低水平炎症和 HIV-1 蛋白暴露引起的神经认知功能障碍。这些实验将确定 DA 受体和 DAT 中神经生物学变化的功能作用,作为一种神经化学机制,即使不介导 HIV-1 转基因的长期表达,也会导致神经认知损伤。该项目的目标是通过与儿科 HIV-1/AIDS 以及 HAND 相关的认知核心组成部分的转化模型来推进该领域的发展,更重要的是,识别(正常大鼠)和验证(特征更好的 HIV-1 转基因大鼠)新型神经治疗药物,以“调整”受 HIV-1 影响的认知领域。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rosemarie M Booze其他文献

Rosemarie M Booze的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rosemarie M Booze', 18)}}的其他基金

Targeting Immunometabolism: a novel role for itaconate in the treatment of HIV-associated neurocognitive disorder and cocaine use disorder
靶向免疫代谢:衣康酸在治疗 HIV 相关神经认知障碍和可卡因使用障碍中的新作用
  • 批准号:
    10700556
  • 财政年份:
    2023
  • 资助金额:
    $ 13.19万
  • 项目类别:
Microglial modulation of neurocircuits in HIV/cocaine comorbidity
HIV/可卡因共病中神经回路的小胶质细胞调节
  • 批准号:
    10762502
  • 财政年份:
    2023
  • 资助金额:
    $ 13.19万
  • 项目类别:
Neurobiological Mechanisms of Apathy in HAND
手部冷漠的神经生物学机制
  • 批准号:
    10202743
  • 财政年份:
    2017
  • 资助金额:
    $ 13.19万
  • 项目类别:
Maternal HIV: Developmental Neurotoxicity
孕产妇艾滋病毒:发育神经毒性
  • 批准号:
    8705551
  • 财政年份:
    2003
  • 资助金额:
    $ 13.19万
  • 项目类别:
Maternal HIV: Developmental Neurotoxicity
孕产妇艾滋病毒:发育神经毒性
  • 批准号:
    9102146
  • 财政年份:
    2003
  • 资助金额:
    $ 13.19万
  • 项目类别:
Maternal HIV: Developmental Neurotoxicity
孕产妇艾滋病毒:发育神经毒性
  • 批准号:
    8467179
  • 财政年份:
    2003
  • 资助金额:
    $ 13.19万
  • 项目类别:
Maternal HIV: Developmental Neurotoxicity
孕产妇艾滋病毒:发育神经毒性
  • 批准号:
    8554771
  • 财政年份:
    2003
  • 资助金额:
    $ 13.19万
  • 项目类别:
Neurodevelopmental Basis(es) of Nicotine Sensitization
尼古丁致敏的神经发育基础
  • 批准号:
    6543815
  • 财政年份:
    2002
  • 资助金额:
    $ 13.19万
  • 项目类别:
Neurodevelopmental Basis(es) of Nicotine Sensitization
尼古丁致敏的神经发育基础
  • 批准号:
    6668464
  • 财政年份:
    2002
  • 资助金额:
    $ 13.19万
  • 项目类别:
Neurodevelopmental Basis(es) of Nicotine Sensitization
尼古丁致敏的神经发育基础
  • 批准号:
    6765214
  • 财政年份:
    2002
  • 资助金额:
    $ 13.19万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了